Navigation Links
MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference
Date:9/20/2012

KENNESAW, Ga., Sept. 20, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane announced today that it will present at the Craig-Hallum 3rd Annual  Alpha Select Conference in New York City.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Thursday, September 27th, at 3:30 p.m. Eastern Time at the Sentry Centers.  A webcast of this presentation will be available on the Company's website, www.mimedx.com

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® Process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 90,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.


'/>"/>
SOURCE MiMedx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition
2. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
3. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
4. MiMedx Group Announces Record Second Quarter Results
5. MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
6. MiMedx Group Announces Record First Quarter Results
7. MiMedx Exceeds Revenue Goal for First Quarter of 2012
8. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
9. MiMedx Group Announces 2011 Results
10. MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting
11. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... January 20, 2017 Stock-Callers.com explores ... have influenced the most recent performances of select equities. ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... Grand View Research, global Biotech market size is expected to reach $604.40 ...
(Date:1/20/2017)... 2017 http://www.Financialbuzz.com - ... leading causes of death worldwide. There were 8.2 million ... cancer related deaths increased gradually over time, the death ... of various cancers continues to drive demand of biological ... Global Market Insights, Inc. cancer biological therapy market size was ...
(Date:1/19/2017)... 2017 Research and Markets has announced the ... Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... market is projected to reach $15,737 million by 2022 from $6,521 ... 2022. Omic technologies segment accounted for more than ...
(Date:1/19/2017)... and HOUSTON , Jan. 19, ... today announced the formation of its Medical/Clinical Advisory ... and industry veterans who enhance the range and ... accelerates development of its novel prenatal diagnostic tests.  ... clinical and strategic guidance for the company,s product ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/8/2016)... Dec. 8, 2016  Singulex, Inc., the leader in ... entered into a license and supply agreement with Thermo ... agreement provides Singulex access to Thermo Scientific BRAHMS PCT ... is used to diagnose systemic bacterial infection and ... to aid in assessing the risk of critically ...
(Date:12/7/2016)... , Dec. 7, 2016   Avanade ... successful Formula One teams in history, exploit biometric data ... stop performance and maintain the competitive edge against their ... 2016. Avanade has worked with Williams ... range of biometric data (heart rate, breathing rate, temperature ...
Breaking Biology News(10 mins):